An interventional study of Tirzepatide and Anti-Hypertensive medications in Hypertension and Obesity & Overweight, sponsored by Cambridge University Hospitals NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-29.
Sponsored by Cambridge University Hospitals NHS Foundation Trust · Not applicable, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 223 studies in Hypertension with a site in United Kingdom — 34 open to participants now, 43 under way, 7 of them phase 3. Hypertension · United Kingdom.
Among the 223 studies in Hypertension with a site in United Kingdom, this one is the 114th largest by planned enrollment of the 172 interventional ones that give a count, is one of 8 that started in 2026, is one of 73 with no phase, reaches primary completion later than 20 of the 42 other live ones, and was the 218th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →34 of the 223 studies in Hypertension with a site in United Kingdom are open now. Recruiting first, the newest first:
CRISPR Therapeutics AG · Sites in United Kingdom, United States, Australia
Ages 18–75
King's College London · Sites in United Kingdom
Ages 10–25 · Healthy volunteers
Northumbria University · Sites in United Kingdom
Ages 18+
Medtronic Vascular · Sites in United Kingdom, Australia, Belgium and 6 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 32 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 27 · Phase 3 48 · Phase 4 20
First in 1997; this study’s year is marked. 8 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 125 across the 172 interventional studies, 200 across the 50 observational. Of the 156 that completed or were terminated, 52 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 223 have an industry lead sponsor. The 10 most frequent:
Cambridge University Hospitals NHS Foundation Trust is the lead sponsor of 172 studies on the registry; 39 are open to participants now.
Cambridge University Hospitals NHS Foundation Trust has 7 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
11 of the studies in Hypertension with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07222917AstraZenecaA Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure. | 2026-12-10 |
| NCT07294794University of BirminghamPersonalised Pharmacometabolomic-guided Strategy Trial to Optimise Treatment for Hypertension | 2026-12-31 |
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2027-01 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 223 studies in Hypertension with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hypertension is the leading risk factor for death globally, affecting approximately 30% of adults in the United Kingdom. Obesity is also a serious and ongoing epidemic, with global obesity rates having more than tripled in men and doubled in women, since 1975. In the United Kingdom, 64% of the adult population are overweight or obese. Hypertension and obesity share a well-established association, with obesity being responsible for the development of hypertension in 40-78% of cases. In young adults, this link between body size and blood pressure (BP) is much stronger that in older adults. Since overweight and obesity are among the most common and modifiable causes of high BP, weight loss induced by lifestyle-changes is recommended for overweight or obese patients with hypertension. However, lifestyle interventions, even when successful, result in only moderate weight loss, which is not maintained in the majority of cases. A meta-analysis of randomised controlled trials demonstrated that lifestyle-interventions lead to an average net weight reduction of 5.1 kg, accompanied by a significant, but modest, \~4 mmHg reduction in BP. Weight loss interventions could play a crucial role in the treatment of obesity-related hypertension in young adults.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, originally developed for the treatment of type 2 diabetes, are safe and clinically effective anti-obesity drugs. Recent data show a 10-20% placebo-adjusted reduction in body weight in overweight or obese adults without diabetes using the GLP-1 analogue semaglutide or the dual GLP-1/GIP receptor agonist tirzepatide, with the majority of weight loss achieved within the initial six months. The substantial weight loss induced by these drugs is accompanied by a significant reduction in BP. Two recent meta-analyses showed that semaglutide is associated with a \~5 mmHg placebo-adjusted reduction in clinic systolic BP (SBP). A sub-study of the SURMOUNT-1 trial reported a \~10 mmHg reduction in 24-h ambulatory SBP with tirzepatide. Most participants in these studies were normotensive or had well-controlled hypertension. Furthermore, antihypertensive medication use declined amongst those receiving anti-obesity drugs meaning the BP-lowering effect of weight loss, elicited by these drugs, is probably underestimated. These data suggest that the new anti-obesity drugs could be effective in managing overweight or obesity-related hypertension. Furthermore, it may be possible to cure hypertension in at least some young adults, removing the need for life-long antihypertensive treatment. However, the magnitude and time course of BP reduction elicited by these new anti-obesity drugs remain uncertain.
The primary aim of this feasibility study is to assess the extent and trajectory of BP reduction achieved through intensive weight loss in overweight or obese adults with stage 1 hypertension and compare this to current standard of care measures which uses anti-hypertensive medications and lifestyle advice. The study will utilise a modified trial within cohort approach, using patients based within the clinical pharmacology/hypertension service at Addenbrooke's Hospital, Cambridge.
Eligibility criteria for randomisation
Inclusion Criteria:
Exclusion Criteria:
Eligibility criteria for participation in weight loss arm
Inclusion criteria:
Exclusion criteria:
The presence of any of the following will preclude participant inclusion:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6 months of treatment with a combined GLP-1/GIP receptor agonist, tirzepatide
Drug: Tirzepatide
Drug: Anti-Hypertensive medications
2.5mg for 4 weeks, 5mg for 4 weeks, 7.5mg for 4 weeks, 10mg for 12 weeks
Anti-hypertensive drug therapy as per local and national guidelines
Ambulatory systolic blood pressure
Change in daytime ambulatory systolic blood pressure in the weight loss arm
Time frame: Baseline to week 24
Ambulatory diastolic blood pressure
Change in daytime ambulatory diastolic blood pressure in the weight loss arm
Time frame: Baseline to week 24
Clinic systolic blood pressure
Changes in clinic systolic blood pressure in the weight loss arm
Time frame: Baseline to week 24
Clinic diastolic blood pressure
Changes in clinic diastolic blood pressure in the weight loss arm
Time frame: Baseline to week 24
Clinic mean arterial pressure
Changes in clinic mean arterial pressure in the weight loss arm
Time frame: Baseline to week 24
Unattended systolic blood pressure
Changes in unattended systolic blood pressure in the weight loss arm
Time frame: Baseline to week 24
Unattended diastolic blood pressure
Changes in unattended diastolic blood pressure in the weight loss arm
Time frame: Baseline to week 24
Unattended mean arterial pressure
Changes in unattended mean arterial pressure in the weight loss arm
Time frame: Baseline to week 24
Body weight
Changes in body weight in the weight loss arm
Time frame: Baseline to week 24
Body fat
Changes in body fat in the weight loss arm
Time frame: Baseline to week 24
Waist:hip ratio
Changes in waist:hip ratio in the weight loss arm
Time frame: Baseline to week 24
Cardiac output
Changes in cardiac output in the weight loss arm
Time frame: Baseline to week 24
Peripheral vascular resistance
Changes in peripheral vascular resistance in the weight loss arm
Time frame: Baseline to week 24
Pulse wave analysis / pulse wave velocity
Changes in markers of pulse wave analysis and pulse wave velocity in the weight loss arm
Time frame: Baseline to week 24
Heart rate variability
Changes in heart rate variability in the weight loss arm
Time frame: Baseline to week 24
Renin
Changes in plasma renin in the weight loss arm
Time frame: Baseline to week 24
Aldosterone
Changes in plasma aldosterone in the weight loss arm
Time frame: Baseline to week 24
Plasma metanephrines
Changes in plasma metanephrines in the weight loss arm
Time frame: Baseline to week 24
Leptin
Changes in leptin in the weight loss arm
Time frame: Baseline to week 24
Insulin
Changes in plasma insulin in the weight loss arm
Time frame: Baseline to week 24
Lipid profile
Changes in the lipid profile in the weight loss arm
Time frame: Baseline to week 24
HbA1C
Changes in HbA1C in the weight loss arm
Time frame: Baseline to week 24
Estimated glomerular filtration rate
Changes in eGFR in the weight loss arm
Time frame: Baseline to week 24
N-terminal pro-B-type natriuretic peptide
Changes in NT-proBNP in the weight loss arm
Time frame: Baseline to week 24
Urine albumin:creatinine ratio
Change in urine albumin:creatinine ratio in the weight loss arm
Time frame: Baseline to week 24
24-hour urine sodium
Change in 24-hour urine sodium in the weight loss arm
Time frame: Baseline to week 24
24-hour urine aldosterone
Change in 24-hour urine aldosterone in the weight loss arm
Time frame: Baseline to week 24
Antihypertensive medications
Change in number of antihypertensive medications
Time frame: Baseline to week 24
Quality of life measures
Changes in quality of life questionnaire scores in the weight loss arm
Time frame: Baseline to week 24
Ambulatory systolic blood pressure
Between-group comparison in ambulatory sytolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Ambulatory diastolic blood pressure
Between-group comparison in ambulatory diastolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic systolic blood pressure
Between-group comparison in clinic systolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic diastolic blood pressure
Between-group comparison in clinic diastolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Clinic mean arterial pressure
Between-group comparison in clinic mean arterial pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended systolic blood pressure
Between-group comparison in unattended systolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended diastolic blood pressure
Between-group comparison in unattended diastolic blood pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Unattended mean arterial pressure
Between-group comparison in mean arterial pressure
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Body weight
Between-group body weight
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Body fat
Between-group comparison in body fat
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Waist:hip ratio
Between-group comparison in waist:hip ratio
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Cardiac output
Between-group comparison in cardiac output
Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)
Peripheral vascular resistance
Between-group comparison in peripheral vascular resistance
Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)
Pulse wave analysis / pulse wave velocity
Between-group comparison in markers of pulse wave analysis and pulse wave velocity
Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)
Heart rate variability
Between-group comparison in heart rate variability
Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)
Plasma renin
Between-group comparison in plasma renin
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Plasma aldosterone
Between-group comparison in plasma aldosterone
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Plasma metanephrines
Between-group comparison in plasma metanephrines
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Lipid profile
Between-group comparison in lipid profile
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
HbA1C
Between-group comparison in HbA1C
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Estimated glomerular filtration rate
Between-group comparison in eGFR
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
N-terminal pro-B-type natriuretic peptide
Between-group comparison in NT-proBNP
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Urine albumin:creatinine ratio
Between-group comparison in urine albumin:creatinine ratio
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
24-hour urine sodium
Between-group comparison in 24-hour urine sodium
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
24-hour urine aldosterone
Between-group comparison in 24-hour urine aldosterone
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Number of antihypertensive medications
Between-group comparison in the number of anti-hypertensive medications
Time frame: Change from baseline to week 24 (weight loss arm) and 6 months (standard of care arm)
Quality of life measures
Between-group comparison in quality of life questionnaire scores
Time frame: At week 24 (weight loss arm) and 6 months (standard of care arm)
Plan to share: Yes — Following publication, the data that support the findings of this study will be available from the Chief Investigator/corresponding author upon reasonable request
Supporting information: Study protocol, Clinical study report
Access criteria: Following publication, the data that support the findings of this study will be available from the Chief Investigator/corresponding author upon reasonable request
No publications or documents are linked to this record.
Start is estimated for Jan 2026; primary completion for Jan 2027, 12 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
Cambridge University Hospitals NHS Foundation Trust →